Forbion Has Raised €2.3 Billion for Biotech Funds
The firm successfully secured capital to support the growth of approximately 30 new companies in the sector.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe private venture capital investment effectively accelerates the development of necessary medical treatments?
Biotech investment firm Forbion has raised €2.3 billion, equivalent to $2.6 billion, through two new funds. This capital will be deployed to support roughly 30 high-potential portfolio companies.
Why it matters
The fundraising effort aims to provide crucial financing to biotech firms during a period marked by a significant market shortage of available capital.
Forbion has reached approximately €7.5 billion in total assets under management. Its portfolio has historically produced 21 approved medical products that have impacted 1.6 million patients.
The players
Forbion
This is a venture capital firm headquartered in Naarden, The Netherlands, that specializes in investing in life sciences and biotechnology companies.
Eli Lilly and Company
This is a global pharmaceutical corporation that participated as an investor in the new Forbion funds.
The details
The funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, drew participation from both existing and new investors, including MN, PGGM, KfW Capital, Kauffman Foundation, and Eli Lilly and Company. Since its inception, the firm has financed 142 companies and created 37 organizations.
Timeline
October 6, 2026: Forbion announced the completion of its €2.3 billion fundraising effort.
The Tech Race
This successful fundraising round reflects the ongoing biotech industry capital shortage that has constrained growth across the sector. By securing substantial capital, Forbion positions itself to sustain innovation pipelines that might otherwise stall due to current market liquidity challenges.
Increased funding for biotech startups accelerates the development of new medical products that could eventually reach patient care. Investors and industry stakeholders should monitor how this capital is deployed across the 30 planned portfolio investments to identify potential clinical advancements.
The takeaway
Large-scale venture capital injections are critical for keeping the pipeline of medical innovation flowing during economic downturns. Identifying which sectors attract this level of institutional backing can help observers understand the most promising areas for future healthcare breakthroughs.
Further reading
Learn more about the latest innovations and market movements in the industry at Biotech.
Live Poll
Do you believe private venture capital investment effectively accelerates the development of necessary medical treatments?
